Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech Shares Phase 3 Interim Results of COVAXIN, Shows 81% Efficacy on Nasdaq: OCGN
European Commission grants Ocugen orphan drug designation for gene therapy product candidate, OCU400, for the treatment of both retinitis Pigmentosa and Leber’s congenital amaurosis
